Participants 137 162 3
metastatic breast cancer.
Participants 284 398 5
patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predeterm
Participants 868 996 6
LTS Despite over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuati
